Adenosine: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
==Overview== | ==Overview== | ||
'''Adenosine''' (ADO) is a [[purine]] [[nucleoside]] comprising a [[molecule]] of [[adenine]] attached to a [[ribose]] sugar molecule ([[ribofuranose]]) [[functional group|moiety]] via a β-N<sub>9</sub>-[[glycosidic bond]]. | |||
Adenosine plays an important role in [[biochemistry|biochemical]] processes, such as energy transfer — as [[adenosine triphosphate]] (ATP) and [[adenosine diphosphate]] (ADP) — as well as in [[signal transduction]] as [[cyclic adenosine monophosphate]], cAMP. It is also an inhibitory neurotransmitter, believed to play a role in promoting sleep and suppressing arousal. | |||
Adenosine also plays a role in regulation of blood flow to various organs through [[vasodilation]].<ref name="pmid15772334">{{cite journal|last=Sato|first=A|author2=Terata, K|author3=Miura, H|author4=Toyama, K|author5=Loberiza FR, Jr|author6=Hatoum, OA|author7=Saito, T|author8=Sakuma, I|author9= Gutterman, DD|title=Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.|journal=American journal of physiology. Heart and circulatory physiology|date=April 2005|volume=288|issue=4|pages=H1633–40|pmid=15772334|doi=10.1152/ajpheart.00575.2004}}</ref><ref name="pmid9576114">{{cite journal|last=Costa|first=F|author2=Biaggioni, I|title=Role of nitric oxide in adenosine-induced vasodilation in humans|journal=Hypertension|date=May 1998|volume=31|issue=5|pages=1061–4|pmid=9576114|doi=10.1161/01.HYP.31.5.1061}}</ref><ref name="pmid1884445">{{cite journal|last=Morgan|first=JM|author2=McCormack, DG|author3= Griffiths, MJ|author4= Morgan, CJ|author5= Barnes, PJ|author6= Evans, TW|title=Adenosine as a vasodilator in primary pulmonary hypertension|journal=Circulation|date=September 1991|volume=84|issue=3|pages=1145–9|pmid=1884445|doi=10.1161/01.CIR.84.3.1145}}</ref> | |||
==Category== | ==Category== | ||
==FDA Package Insert== | ==FDA Package Insert<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher = | date = | accessdate = }}</ref>== | ||
'''| [[Adenosine indications and usage|Indications and Usage]]''' | '''| [[Adenosine indications and usage|Indications and Usage]]''' | ||
Revision as of 17:04, 11 March 2014
| Adenosine |
|---|
| ADENOCARD®, ADENOSCAN® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| Clinical Studies |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Adenosine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Synonyms / Brand Names: ADENOCARD®, ADENOSCAN®
Overview
Adenosine (ADO) is a purine nucleoside comprising a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.
Adenosine plays an important role in biochemical processes, such as energy transfer — as adenosine triphosphate (ATP) and adenosine diphosphate (ADP) — as well as in signal transduction as cyclic adenosine monophosphate, cAMP. It is also an inhibitory neurotransmitter, believed to play a role in promoting sleep and suppressing arousal.
Adenosine also plays a role in regulation of blood flow to various organs through vasodilation.[1][2][3]
Category
FDA Package Insert[4]
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
References
- ↑ Sato, A; Terata, K; Miura, H; Toyama, K; Loberiza FR, Jr; Hatoum, OA; Saito, T; Sakuma, I; Gutterman, DD (April 2005). "Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease". American journal of physiology. Heart and circulatory physiology. 288 (4): H1633–40. doi:10.1152/ajpheart.00575.2004. PMID 15772334.
- ↑ Costa, F; Biaggioni, I (May 1998). "Role of nitric oxide in adenosine-induced vasodilation in humans". Hypertension. 31 (5): 1061–4. doi:10.1161/01.HYP.31.5.1061. PMID 9576114.
- ↑ Morgan, JM; McCormack, DG; Griffiths, MJ; Morgan, CJ; Barnes, PJ; Evans, TW (September 1991). "Adenosine as a vasodilator in primary pulmonary hypertension". Circulation. 84 (3): 1145–9. doi:10.1161/01.CIR.84.3.1145. PMID 1884445.
- ↑ "ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.]".